This action makes these agents a therapeutic option for weight loss.56 Although to a lesser extent, delay in gastric emptying contributes to the anorexigenic effect.61 Clinical trials conducted with GLP-1 receptor agonists in patients with obesity (or excess weight [BMI 27] with comorbidities), or with DT2 and excess weight or obesity, have achieved weight reductions greater than those reported for orlistat, as well as those observed with oral antidiabetic agents such as the sodium glucose type 2 cotransporter inhibitors (SGLT2i) or metformin.62 In a meta-analysis of more than 10 000 patients with obesity, those treated with GLP-1 receptor agonists lost, on average, 7kg more than those in the control group.63 Weight loss of up to 15% has been observed after 12 months of treatment,64,65 a level that had only been achieved through surgical methods
Novel technology for storage and distribution of live vaccines and other biological medicines at ambient temperature
In patients with clinical evidence or subclinical evidence of CV disease and received standard of care for T2DM, treatment with either dose of SEM for 30 weeks was associated with greater reduction in body weight, compared with placebo
PubMed Khavinson VKh, Morozov VG (2003)
